![](https://parkinsonsblog.stanford.edu/wp-content/uploads/2017/09/red-2214221_640.jpg)
The FDA has approved amantadine in a new formulation for the dyskinesia in Parkinson’s patients based on a Phase 3 randomized, double-blind, placebo-controlled study reported in JAMA Neurology.
Read more about the study’s findings on the American Council on Science and Health website.